Retatrutide is a multi-functional peptide drug that acts as an agonist of the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors
Important considerations for both medications BMI and Co-morbidities : Both are typically prescribed for individuals with a BMI 30, or 27 with weight-related conditions
118 showed that GLP-1RAs with metformin improved glucose metabolism and IR, evidenced by reductions in HbA1c (by 0.9%), FBG (by 12 mg/dL), and HOMA-IR decreased by 0.6)
Many patients report significant changes in hunger levels, fullness cues, and even food preferences
If GLP-1 medication doses cannot be increased due to side effects, doctors will consider all options for other medications and for optimizing lifestyle, such as nutrition, exercise and sleep, to support the patients goals.